ammonium hydroxide and Fever studies

Fever: An abnormal elevation of body temperature, usually as a result of a pathologic process.

Research Excerpts

Excerpt	Relevance	Reference
" Fever is a complex interplay of immune, metabolic, and stress responses, yet its benefit in autistic disorders (ASD) may derive largely from a single response - release of the amino acid glutamine from skeletal muscles as provisional fuel."	7.79	Does infectious fever relieve autistic behavior by releasing glutamine from skeletal muscles as provisional fuel? ( Good, P, 2013)
" Fever is a complex interplay of immune, metabolic, and stress responses, yet its benefit in autistic disorders (ASD) may derive largely from a single response - release of the amino acid glutamine from skeletal muscles as provisional fuel."	3.79	Does infectious fever relieve autistic behavior by releasing glutamine from skeletal muscles as provisional fuel? ( Good, P, 2013)
" Safety endpoints included adverse events, hyperammonemic crises (HACs), and growth and development."	1.46	Safety and efficacy of glycerol phenylbutyrate for management of urea cycle disorders in patients aged 2months to 2years. ( Berry, SA; Diaz, GA; Ficicioglu, C; Harding, CO; Lichter-Konecki, U; Longo, N; McCandless, SE; Robinson, B; Smith, WE; Vockley, J; Zori, R, 2017)
" The results show that a binge dosing regimen of METH to the rat increased plasma and brain ammonia concentrations that were paralleled by evidence of hepatotoxicity."	1.38	Peripheral ammonia as a mediator of methamphetamine neurotoxicity. ( Halpin, LE; Yamamoto, BK, 2012)
"Fever, psychomotor agitation, and arterial hypertension were more frequently observed preceding episodes of severe intracranial hypertension, and more than 50% of FHF patients with uncontrolled intracranial hypertension sustained severe brain injury in our series."	1.29	Factors associated with severe intracranial hypertension in candidates for emergency liver transplantation. ( Bell, R; Martin, P; Moritz, MJ; Muñoz, SJ; Northrup, B; Radomski, J, 1993)
"Thirty patients who had gastric varices with gastrorenal or gastrocaval collaterals underwent balloon-occluded retrograde transvenous obliteration."	1.29	Balloon-occluded retrograde transvenous obliteration for gastric varices with gastrorenal or gastrocaval collaterals. ( Koito, K; Morita, K; Nagakawa, T; Namieno, T, 1996)
" Although there were not overall group differences in the dose-response data, there was a significant increase in the hypothermia induced by 8-hydroxy(di-n-propylamino)tetralin in sparse fur compared with control mice (p less than 0."	1.28	Brain serotonin2 and serotonin1A receptors are altered in the congenitally hyperammonemic sparse fur mouse. ( Anegawa, NJ; Batshaw, ML; Coyle, JT; Gorry, E; Lucki, I; Qureshi, IA; Robinson, MB, 1992)
"Seizure is a common problem evaluated in pediatric emergency departments."	1.28	Emergency department laboratory evaluation of children with seizures: dogma or dilemma? ( Davis, AT; Nypaver, MM; Reynolds, SL; Tanz, RR, 1992)

Research

Studies (20)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Percentage of Participants With Successful Transition to RAVICTI With Controlled Ammonia (i.e. No Clinical Symptoms and Ammonia < 100 μmol/L): Cohort of 0 Months to <2 Months Participants

Timeframe	Studies, this research(%)	All Research%
pre-1990	9 (45.00)	18.7374
1990's	5 (25.00)	18.2507
2000's	1 (5.00)	29.6817
2010's	5 (25.00)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Berry, SA	1
Longo, N	1
Diaz, GA	1
McCandless, SE	1
Smith, WE	1
Harding, CO	1
Zori, R	1
Ficicioglu, C	1
Lichter-Konecki, U	1
Robinson, B	1
Vockley, J	1
Northrop, NA	1
Halpin, LE	2
Yamamoto, BK	2
Orton, DJ	1
Gifford, JL	1
Seiden-Long, I	1
Khan, A	1
de Koning, L	1
Good, P	1
CONSTANTSAS, NS	1
DANELATOU-ATHANASSIADOU, C	1
Burgery, FJ	1
Fuhrman, FA	1
Linnane, DM	1
Bracken, RM	1
Brooks, S	1
Cox, VM	1
Ball, D	1
Muñoz, SJ	1
Moritz, MJ	1
Bell, R	1
Northrup, B	1
Martin, P	1
Radomski, J	1
Koito, K	1
Namieno, T	1
Nagakawa, T	1
Morita, K	1
Hinnie, J	1
Colombo, JP	1
Wermuth, B	1
Dryburgh, FJ	1
Goldberg, RN	1
Cabal, LA	1
Sinatra, FR	1
Plajstek, CE	1
Hodgman, JE	1
Kruckenberg, SM	1
Cook, JE	1
Feldman, BF	1
Robinson, MB	1
Anegawa, NJ	1
Gorry, E	1
Qureshi, IA	1
Coyle, JT	1
Lucki, I	1
Batshaw, ML	1
Nypaver, MM	1
Reynolds, SL	1
Tanz, RR	1
Davis, AT	1
Jacob, S	1
Holm, E	1
Fischer, B	1
Burger, FJ	2
Du Plessis, JP	1
Bieler, EU	1
Lategan, PJ	1
Hossaini, AA	1
Boyan, CP	1
Engelbrecht, FM	1
Jordaan, EM	1
Bester, P	1
Huttenlocher, PR	1
Schwartz, AD	1
Klatskin, G	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
An Open Label Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate (GPB; RAVICTI®) in Pediatric Subjects Under Two Years of Age With Urea Cycle Disorders (UCDs)[NCT02246218]	Phase 4	27 participants (Actual)	Interventional	2014-12-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

"The percentage of participants with successful transition is based on Investigator response to the question, Has transition to 100% RAVICTI been successful with controlled ammonia? For participants < 2 months of age, after a minimum of 24 hours of ammonia monitoring following the first full dose of RAVICTI alone, the participant was effectively transitioned when following conditions were met: no signs and symptoms of hyperammonemia; ammonia level less than 100 μmol/L (without normalization of ammonia, ie, without conversion of values from local laboratories with varying normal ranges to standardized values); and eligible for discharge per Investigator judgment." (NCT02246218)
Timeframe: Up to Day 4

Percentage of Participants With Successful Transition to RAVICTI With Controlled Ammonia (i.e. No Clinical Symptoms and Ammonia < 100 μmol/L): Cohort of 2 Months to <2 Years Participants

Intervention	percentage of participants (Number)
RAVICTI: Age 0 to < 2 Months	100

"The percentage of participants with successful transition is based on Investigator response to the question, Has transition to 100% RAVICTI been successful with controlled ammonia? For participants 2 months of age and older, after a minimum of 24 hours of ammonia monitoring following the first full dose of RAVICTI alone, the participant was effectively transitioned when following conditions were met: no signs and symptoms of hyperammonemia; ammonia level less than 100 μmol/L (without normalization of ammonia, ie, without conversion of values from local laboratories with varying normal ranges to standardized values); and eligible for discharge per Investigator judgment." (NCT02246218)
Timeframe: Up to Day 4

Plasma PAA AUC(0-last) on the First Full Day of RAVICTI Dosing: Cohort of 0 Months to <2 Months Participants

Intervention	percentage of participants (Number)
RAVICTI: Age 2 Months to < 2 Years	100